EUR/USD
1.17141
-0.046%
Gold
3367.53
-0.165%
Oil
63.540
-0.240%
USD/JPY
147.191
0.160%
GBP/USD
1.35145
-0.026%
GBP/JPY
198.925
0.145%
Real-time News
On August 25th, UBS published a research report stating that Hengan (01044.HK)s revenue and net profit fell by 0.2% and 2.6% respectively in the first half of 2025. Excluding foreign exchange gains, net profit is expected to fall by approximately 12% during the period, roughly in line with the banks expectations. During the period, revenue from the tissue business increased by 3% year-on-year, while revenue from the sanitary napkin business decreased by 14% year-on-year. Management pointed out that wet wipes performed steadily and competition in the tissue market was better than expected, but sales of sanitary napkins and mid-to-low-end diapers declined due to intensified competition. Looking ahead, the group expects tissue sales to grow steadily and the gross profit margin of sanitary products to improve in the second half of 2025. UBS raised Hengans earnings forecast for 2025 to 2027 by 1% to 4% and its revenue forecast by 1% to 2%. It also raised its target price from HK$27.7 to HK$29.5 and maintained its buy rating.Kazakhstans Energy Ministry: Oil exports were not affected after the Ukrainian drone attack on the Russian port of Ust-Luga.On August 25th, Goldman Sachs raised its earnings per share forecast for WuXi Biologics (02269.HK) from 2019 to 2027 by 11.9% to 15.9%, reflecting better-than-expected gross profit margin improvements. The target price was raised from HK$25.6 to HK$29.3, while the target price-to-earnings ratio remained at 23x. The rating was neutral. The bank reported that the companys interim gross profit margin expanded by 3.6 percentage points year-over-year to 42.7%, driven by a reduction in employee share-based compensation, increased milestone revenue from the R phase of the research, and improved utilization of new production capacity, offsetting losses from the Irish project. The report indicates that management expects the gross profit margin improvement to continue in the second half of the year. Based on increased operating efficiency and capacity utilization, the long-term gross profit margin target is 50%, with the Singapore plants gross profit margin expected to reach approximately 45%.On August 25th, Daiwa Research published a research report, giving Yuejiang (02432.HK) its first-ever Buy rating and a target price of HK$65.50. The report believes the company will become a competitive humanoid robot company, leveraging its leadership in the collaborative robot (cobot) market to gain a competitive advantage over its peers and generate long-term revenue growth. The report notes that according to Yuejiangs management guidance, the company will achieve break-even once revenue reaches US$100 million. The bank anticipates that the companys net loss will narrow to approximately RMB 10 million in 2026, driven by rising cobot sales and stable gross profit margins, putting the company nearing break-even by then.On August 25th, UBS published a research report stating that Simcere Pharmaceuticals (02096.HK)s interim results exceeded expectations, with revenue and net profit increasing by 15.1% and 32.2% year-on-year, slightly exceeding the banks forecast. Management reiterated its guidance for at least 15% revenue and adjusted profit growth in 2025, and forecast revenue and net profit to reach RMB 11 billion and RMB 2 billion respectively by 2027. UBS raised its target price for Simcere Pharmaceuticals from HK$14.5 to HK$16.3, maintaining its Buy rating. The bank lowered its long-term R&D expenditure forecast and raised its EPS forecasts for 2025, 2026, and 2027 by 1.1%, 3.9%, and 7.4%, respectively.
